Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats

RRx-001 is a small molecule NLRP3 inflammasome inhibitor with anti-CD47 and antiangiogenic/vascular normalization properties in a Phase 3 clinical trial that has been designated as a drug-device combination by the FDA. In the Phase 1 first-in-man dose escalation clinical trial, where RRx-001 was giv...

Descripción completa

Detalles Bibliográficos
Autores principales: Caroen, Scott, Oronsky, Bryan, Reid, Tony, Pandher, Karamjeet, Lopez, Alric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553854/
https://www.ncbi.nlm.nih.gov/pubmed/36237984
http://dx.doi.org/10.7150/ijms.76615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553854/
https://www.ncbi.nlm.nih.gov/pubmed/36237984
http://dx.doi.org/10.7150/ijms.76615

Ejemplares similares